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Wise in One’s Own Conceit: The Effect of Direct-to-Consumer Advertising (DTCA) in 
Consumer’s Perceived Medical Knowledge 
Rachel Banton 
The pharmaceutical industry uses various marketing tactics directed to both health care 
professionals and consumers alike. Advertising directly to consumers has proven 
controversial. Critics argue that direct-to-consumer advertising (DTCA) promotes 
overmedicalization and unwarranted demand for prescription drugs. This study 
investigated (1) whether consumers’ level of knowledge about a disease or perceived 
knowledge causes them to seek information from a physician and (2) whether DTCA 
increases consumers’ perceptions of their level of disease knowledge. Results suggest 
that DTCA has no meaningful impact on perceived knowledge and intention to 
communicate with the physician. However, consumers’ perceived level of knowledge 
predicted intention to communicate with the physician. These findings have numerous 
implications for the pharmaceutical industry, regulators and patients alike. 
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Pharmaceutical companies are unique enterprises within the global market, 
making this industry an important one to analyze and understand. The pharmaceutical 
industry is considered one of the most profitable industries, with an 18.6% return on 
revenue compared to the next highest industry, commercial banks, at 14.1% (Reinhardt, 
2001). Another factor that makes pharmaceuticals an important industry is its financial 
contribution to the global economy. In 2012, the pharmaceutical industry spent $26.35 
billion on promotion (Cegedim Strategic Data, 2012) and in 2007 spent $58.8 billion in 
R&D (PhRMA, 2009). Equally important is the role that the pharmaceutical industry 
plays in modern day health care. Physicians write on average 3 billion prescriptions a 
year (Posey, 2001). That number continues to increase; in 2011, the number of 
prescriptions rose to 4.02 billion (Science Daily, 2012). In 2008, 74% of patient visits to 
the physician office were in regards to drug therapy (Center for Disease Control, 2008). 
In addition to the pharmaceutical industry’s importance within the global market, its 
marketing practices are defined by several key attributes that distinguish it from other 
industries and make it particularly worthy of study. 
 The pharmaceutical industry distributes its product to consumers via physicians 
and this presents unique marketing challenges. This type of marketing is distinct, as 
pharmaceutical marketers are not always advertising to the end-user of their product.   
The primary form of marketing used by the pharmaceutical industry remains a push 
strategy, whereby sales representatives promote products to physicians and offer samples 
of new products (Buckley, 2004). The majority of the pharmaceutical industry’s $25 
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billion promotional spend goes toward physician detailing (Auton, 2006). In 2005, the 
pharmaceutical industry employed over 100,000 sales representatives (one for every six 
practicing physicians) who collectively made on average 6 million visits to physicians 
that year (Pollack, 2009). In 2003, the U.S. pharmaceutical industry spent more on push 
marketing than any other form of promotion. During that year, the industry as a whole 
spent approximately $7.13 billion in detailing and $13.04 billion in sampling costs (IMS 
Health, 2004). 
 In order to try to improve their marketing effectiveness, a second form of 
promotion used by the pharmaceutical industry is a pull strategy. Using DTCA, products 
are promoted to consumers through various media such as print and television 
advertisements (Frosch et al., 2007). There are three main types of DTC ads (Gardner, 
Mintzes & Ostry, 2003). Product claim ads advertise the prescription drug and the disease 
it treats. Reminder DTC advertisements state the drug name without telling the viewer 
what diseases or indications the product treats. Finally, help-seeking, or disease 
awareness ads, inform consumers of new treatments for a disease without specifically 
mentioning the company’s brand of drug developed for that disease. According to the 
FDA, only product claim ads require risk information, as the latter two forms are not 
informative enough to require risk disclosure (Mintzes, Barer, Lexchin & Bassett, 2005).  
Risk disclosure and other issues have made the use of DTCA by the 
pharmaceutical industry a contentious one. Certain scandals have only heightened this 
controversy. For example, in September 2004, Merck & Co. announced that it would be 
voluntarily withdrawing its $2.5 billion a year grossing COX-2 inhibitor, rofecoxib, from 
the market. Rofecoxib, or Vioxx, was approved by both Health Canada and the Food and 
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Drug Administration in 1999 (Green, 2006). By 2004, there was mounting evidence that 
Vioxx was causing an increase in cardiovascular events in patients taking the drug as a 
long-term treatment (Sibbald, 2004). After the withdrawal, many pundits and regulators 
raised concerns over the incident and questioned why it took so long for these side effects 
to be discovered, particularly when a Merck-sponsored study in 2000 suggested Vioxx 
may cause an increased risk of cardiovascular events (Green, 2006; Kelly, 2004; Pollack 
et al., 2009). 
The Vioxx incident increased scrutiny over many aspects of the pharmaceutical 
industry, including its marketing tactics. One such aspect was the pharmaceutical 
industry’s practice of marketing drugs directly to the end-user via DTCA. This practice 
was put into focus particularly given Vioxx’s widespread use, with an estimated 105 
million prescriptions written from 1999 to 2004 (Business Wire, 2004). In addition, as 
Vioxx was a ‘me too’ drug (a drug to market that is not the first of it’s kind in terms of 
chemical structure or mechanism of action) it should theoretically not have made such a 
leap in sales, placing it so close to the market leader, Pfizer’s Celebrex. Therefore, it has 
been argued that were it not for intense use of DTCA ($160.8 million compared to 
Celebrex’s $78.3 million DTCA spend in 2000) (Green, 2006), Vioxx’s effects would not 
have been as widespread. 
This example demonstrates the interplay between many of the areas which are the 
focus of this thesis. First, much of the contention surrounding DTCA concerns whether it 
stimulates unwarranted demand for prescription drugs, what has come to be known as 
overmedicalization (Mintzes, 2006; Moynihan, Heath & Henry, 2002; Mintzes et al., 
2003) The Vioxx situation demonstrates how serious a problem DTCA can pose if it 
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causes increased prescribing and use of a drug for which there are unforeseen risks 
(Gardner, et al., 2003). Second, it demonstrates the importance of patient-physician 
interactions and how important a role this plays in what gets prescribed. For example, 
individuals who saw DTCA and requested their physician to prescribe a COX-2 inhibitor 
were more likely to be prescribed that type of medication compared to another 
nonsteroidal anti-inflammatory drugs (NSAID), particularly for arthritis (Spence et al., 
2005).  
Second, this example shows that the role the patient plays in the pharmaceutical 
marketing process cannot be understated. Whether the patient decides to visit the 
physician, receives a prescription from their physician, complies with the regimen by 
even going to fill their prescription are all huge filters on whether the drug is actually 
consumed by the patient and the profit the pharmaceutical industry earns on their 
promotion dollar. Despite this importance, the current literature on this topic tends to 
look at the aggregate process of pharmaceutical marketing and ignores the importance of 
the patient as an independent agent. Therefore, there is a gap in understanding how the 
micro aspects of the pharmaceutical marketing process function. For example, with the 
exception of a few recent publications (An, 2007) much less is known about the patient-
physician interaction and consumer cognition relating to healthcare advertisements. Even 
less about how these micro processes relate to the larger picture of concepts such as 
medicalization and drug request behavior. In order to truly understand how the larger 
picture works, how it should work and how it should be regulated, there needs to be a 
better understanding of how consumers are processing drug advertising and how patients 
interact with their physician in the examination room.  
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To help close these gaps, this research was undertaken to investigate the 
relationship among these key variables. Specifically, this research posits that there is a 
link between medicalization, the patient-physician relationship, DTCA and consumer’s 
cognitive processing of drug advertisements.   
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RESEARCH OBJECTIVES  
 
 The first objective of this research is to explore what influence DTCA may have on 
consumer’s health-related decisions. Currently, there is circumstantial support on each 
side. Those against DTCA have many concerns about the use of this form of promotion. 
Imagine a patient is swayed by DTCA to request the newest form of medication to treat 
their disease. Although the drug is approved, it is relatively new compared with the older, 
just as efficacious drug that is off-patent and no longer being advertised to the consumer. 
And as with what happened in Vioxx, there is always the risk that a new drug could have 
unforeseen risks. Conversely, proponents of DTCA argue that this promotional technique 
is educational and helps to raise awareness about untreated diseases. To date, no study 
has conclusively investigated, using an experimental design, the psychological processing 
of DTCA by the consumer and how this affects consumer behavior.  
 In addition to shedding light on the DTCA debate for regulatory purposes, 
determining what is occurring with patients when they process DTCA can help inform 
the medicalization debate. In a similar vein, there exists a gap within the medicalization 
literature that needs to be addressed. Much of the medicalization literature simply 
supposes that DTCA is a mechanism by which overmedicalization occurs without really 
demonstrating what mechanisms underlie this effect. There seems to be an assumption in 
this research that patients see an ad and then act upon seeing this information advising 
them to speak with their doctor. It does not take into account the consumer is an agent in 
and of themselves. For example, the SOR model (Woodworth, 1928) states that the 
organism is a mediating variable between the stimulus and response. Rather than ignoring 
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the consumer’s interpretation of incoming information from DTCA, another objective of 
his thesis is to offer one concrete explanation of the mechanism underlying 
medicalization. In particular, what about DTCA leads consumers to have a conversation 
with their physician about the drug or even request the advertised drug? 
 Another aim of this thesis is to offer information that would help pharmaceutical 
marketers and regulators alike make better-informed and sounder decisions pertaining to 
DTCA. For example, if DTCA is promoting overmedicalization by persuading consumers 
who need not be persuaded to speak with their physician about a new drug, this thesis 
may be able to show regulators how to approach this issue. If the mechanism by which 
this is occurring is that consumers do no have enough knowledge to make informed 
healthcare decisions for themselves, then regulators now have practical information that 
would indicate that one way to combat this problem is by issuing more and better 
objective information to the public. The results of this thesis could also help those in the 
pharmaceutical industry. If the pharmaceutical industry were given information on how 
consumer’s cognitive processing is influencing patients’ willingness to speak to their 
physician about the drug, they would be in possession of a new psychographic variable 
with which to segment their market and better tailor advertising accordingly.   
 The final objective of this research is to extend Kruger and Dunning’s 
unskilled/unaware framework in a new context. Kruger and Dunning’s (1999) 
unskilled/unaware hypothesis has not been tested in the healthcare area to date. 
Therefore, this thesis will be a test of this model’s validity in this new context. 
Additionally, this hypothesis has been largely tested using student samples. If this model 




 Given the existing gaps in the literature and the objectives of this research, the 
following questions are the focus of this thesis: 
 One of the main questions to be answered by this research deals with whether the 
cognitive theory dealing with individual’s lack of insight into their own knowledge can 
be applied to a the healthcare domain (Kruger & Dunning, 1999). This research will 
determine how well the unskilled/unaware hypothesis holds in a knowledge domain in 
which participants may not necessarily be familiar with. Given these gaps in knowledge 
about the boundaries of the unskilled/unaware hypothesis, the following question was 
asked: 
Q1:  Does one’s level of knowledge influence one’s level of metacognitive ability  
  within the healthcare domain? 
 Prior research in the unskilled/unaware area has demonstrated that the link between 
participant’s domain-specific knowledge and metacognitive ability in that domain can be 
altered through experience. Therefore, it is of interest whether DTCA has an educating 
effect for consumers or rather causes the consumer to merely feel more confident in their 
knowledge. In particular, if DTCA is putting certain consumers at a disadvantage then 
this is evidence that this is one mechanism underlying medicalization. Conversely, if 
DTCA has a positive or no effect on consumer’s drug request behavior, then this thesis 
could provide some evidence that DTCA’s role in overmedicalization has been 
overstated. 
Q2:  Does a DTCA intervention cause low-knowledge level consumers to further  
  overstate their level of knowledge or rather make their insight into their own  
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  level of knowledge more accurate? 
 The third issue addressed in this thesis is whether consumer’s insight into their own 
knowledge can influence their decision to seek information about the drug and potentially 
request a drug from their physician. Consumer’s cognitive processing may influence 
other areas but tying this to this important variable was essential to make this research 
practical and relevant. Therefore, the following question was posed: 
Q3: Does consumer’s metacognitive ability, or understanding of their own 




SOURCES OF HEALTH KNOWLEDGE 
 
 Consumers derive health knowledge from a multitude of sources. More so than 
ever before, consumers are playing a more active role in their own healthcare and seek 
out information from these sources. For example, those conducting information searches 
about health concerns has risen from 38% of American adults in 2001 to 56% in 2007 
(HSC Community Tracking Study Household Survey, 2007). Consumers report seeking 
health information from print (books, magazines, newspapers), friends and relatives, the 
internet and, least often, from television and radio (HSC Community Tracking Study 
Household Survey, 2007). The use of the internet as a health information resources has 
doubled from 2001 (16%) to 2007 (32%) (HSC Community Tracking Study Household 
Survey, 2007). 
 As this data suggests, consumers seek out health information from many sources. 
But what types of individuals are seeking out health information and how are they using 
it? A survey conducted by Fox and Fallows (2003) for Pew Internet and American Life 
found that there are three main clusters of consumers who actively seek health 
information. The first group is those who search for health information on behalf of 
others. This group is mainly composed of healthy women aged 30-49 years old who are 
seeking information on behalf of their children. The next category is individuals with 
chronic illness or disability. Eighty-seven percent of this group has searched the internet 
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at least once regarding health concerns. Similarly, the final group is composed of those 
who are caregivers for individuals with chronic illness or disability.  
 Stemming from consumers growing use of health resources, a new area of 
research has emerged. Consumer health informatics is based on the principle that the 
more health information is readily available to the consumer the better as this improves 
consumers’ knowledge and decision-making capabilities (Eysenbach, 2000). However, 
despite the increasing consumption of health-related knowledge, evidence exists that 
access to information may not always yield better informed patients able to make better 
health choices.  
 Keselman et al. (2008) conducted a study in which they asked participants to 
make a diagnosis given a list of symptoms using the internet as their source of 
information. The researchers grouped participants search strategies into three categories: 
‘verification first’, ‘problem area first’ and ‘bottom up’. The participants who fell into the 
‘verification first’ strategy initiated their search by having a diagnosis in mind. They then 
sought out information to either confirm or refute their original theory. However, subjects 
in this group often committed errors such as confirmation bias and prematurely 
discontinuing their search as soon as they erroneously believed they had found 
confirmation of their hypothesis. Participants using the ‘problem area’ strategy of 
beginning the search with a diagnostic category in mind often did not have enough pre 
requisite domain knowledge to navigate their way through information they discovered. 
For example, they would skip over a subcategory and would end up without any 
conclusion. Participants using a ‘bottom up’ strategy suffered from the same issue of not 
having the requisite knowledge. Participants would fail to account for all symptoms given 
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to them. For example, subjects would often disregard information they would not 
typically associate with cardiac issues (ex: nausea) and then search out a diagnosis that 
conformed to the symptoms as they perceived them.  
 Should a consumer make an incorrect diagnosis of symptoms they may be 
experiencing, they could have this clarified upon a visit to their physician. However, 35% 
of individuals seeking out health information online never confirm their findings with a 
physician (Pew Internet Project Report: Online Health Search as cited in Keselman et 
al., 2008). 
 The easy access to educational health information can be useful in certain cases 
where it helps inform the patient. However, there are risks to consider. As can be seen 
from Keselman et al. (2008), there is the potential that increased patient access to 
information can lead to the consumer drawing erroneous conclusions about theirs, or 
another’s, health. 
 Increased focus on health in combination with easy access to health information 
has in part fueled the debate over what the appropriate level of medicalization should be 




Medicalization as a Form of Social Control 
The notion of medicalization first developed within sociology as a hypothesized means of 
social control. Parsons (1951) was the first to talk about the ‘sick role’ and how labeling 
behavior as an illness could be used as a form of social control over others. This model 
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states that there are certain expectations a sick individual takes on once they are labeled 
as such. It is expected that society will not blame the individual for being sick and this 
person is not expected to be able to cure himself or herself with resolve alone, nor are 
they expected to always be cured via help from other non-sick individuals. Furthermore, 
the sick person is exempted from social, work and family obligations. However, in 
addition to exemptions, the sick person also has obligations to define his being sick as 
negative and must actively want to and participate in getting better (Fox, 1977).  
 Later in the 1970’s, researchers began building upon Parson’s research of the 
‘sick role’ by investigating which social behaviors deemed by society as negative have 
been medicalized and which ones remained bad behavior caused by the individual 
themselves. Some examples of conditions researched that were deemed medicalized 
include hyperactivity in children (Conrad, 1975), mental illness (Scull, 1975), child abuse 
(Pfohl, 1977) and alcoholism (Schneider, 1978).  
 Eliot Freidson and Irving Zola also viewed medicalization as a sociological issue. 
Like researchers before them, they both emphasized the social control aspect of 
medicalization. They argued that the rise in secularization and humanistic ideology are 
both responsible for medicalization (Davis, 2006). Following them, Fox (1977) proposed 
that deviant behavior is dealt with by society in a fairly consistent way across 
civilizations over time. He noted that the evolution of how deviant behavior is construed 
depends on the level of secularization within a society. First, deviant behavior starts as 
being labeled sinful and is to be dealt with by the church. Then, as society grows less 
religious but still clings to some religious ideology, deviant behavior turns criminal, to be 
dealt with by the state. Finally, with increasing focus on science, analytical thinking and 
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increasing secularization, criminal behavior is once again re-labeled and becomes 
perceived as a form of illness to be dealt with by the medical community. 
 Although sociology is where the notion of medicalization originated, it has 
evolved over time. The term is still used to indicate the change of a behavior from being 
interpreted as a typical occurrence, to being labeled as a medical condition. However, 
rather than always carrying a negative connotation as a form of control over the 
population, medicalization now refers to how society as a whole, the medical community 
and the pharmaceutical industry now interpret the boundaries of illness and disease.  
 
Modern-day Medicalization 
 Mirriam-Webster defines medicalization as ‘to view or treat as a medical concern, 
problem or disorder’. The general idea of medicalization has not changed dramatically 
since its conception in the 1950’s. What has changed, most would argue, is where the 
boundary between health and sickness lies. The World Health Organization (WHO) 
defines health as “a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity." (WHO, October 2011). As an authority on 
health, the WHO’s definition is important and reflects what many authors argue is a 
general societal trend to construe more and more of what used to be considered ‘normal’ 
into illness or disease (Brennan, Eagle & Rice, 2010; Davis, 2006). 
 At issue is determining the cause of this narrowing definition of health. Poitras and 
Meredith (2009) make the distinction between two forms of medicalization: social and 
economic. Social medicalization is still interpreted as a way of gaining power (Poitras & 
Meredith, 2009). Brennan et al. (2010) discuss certain social phenomena and actors that 
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may contribute to medicalization. The theory of medical imperialism states the medical 
community actively seeks to medicalize previously normal behavior in order to gain 
power. Political forces can also play a role in medicalization. Advocacy groups can 
actively petition for something to be medicalized in order to gain power for those 
diagnosed with the illness. For example, patient advocacy groups played a large role in 
having post-traumatic stress disorder labeled as such (Brennan et al., 2010). 
Technological advances can also play a role in the increase of medicalization in society. 
Better technology is now available to diagnose diseases earlier, or detect symptoms that 
may not have been traceable before. Advances in statistics now allow for a better 
understanding of potential risk factors for disease and thus, an illness may be treated 
based on risk-factors even before a disease arises. Demographic factors also play a 
possible role. In North America, baby boomers are aging, and thus there is a large 
segment of the population seeking medical solutions that previous generations never 
considered as falling under the purview of medicine.  
 Economic medicalization is the transformation of non-medical problems into 
medical ones to the benefit of pharmaceutical companies (Poitras & Meredith, 2009). 
Overmedicalization stems from a multitude of factors including social trends, 
pharmaceutical industry factors and mass media medical reporting (Brennan et al., 2010). 
However economic medicalization and the pharmaceutical industry’s use of DTCA have 
been particularly blamed for increases in medicalization and inappropriate demand for 





The Rise of Direct-to-Consumer Advertising 
 How did the marketing of pharmaceuticals reach the point it is at today? Why are 
certain stakeholders concerned about the presence of DTCA as a marketing tool in the 
pharmaceutical industry? Understanding the case of the evolution of DTCA in the United 
States is of particular importance for several reasons. First, it is one of the few countries 
where all forms of DTCA are permitted (Frosch et al., 2007). Furthermore, U.S. markets 
make up approximately 48% of global pharmaceutical sales (Auton, 2006). 
Understanding the evolution of DTCA within this market will make clear DTCA policy 
initiatives that have already taken place and what might be the correct path moving 
forward in light of the results of this research. 
 In 1962, the United States Congress granted the Food and Drug Administration 
(FDA) authority to regulate pharmaceutical marketing (Aikin et al. as cited in Boden & 
Diamond, 2008). Then, in 1969, the FDA passed regulation stating that pharmaceutical 
advertising must present a ‘fair and balanced’ assessment of the risks and benefits of the 
advertised drug (Boden & Diamond, 2008).  In the 1980s spending on DTCA industry-
wide was only about $12 million (Deshpande et al. 2004; Palumbo & Mullins, 2002). 
DTCA as we know it today got its start in the United States in 1997. It was then that the 
FDA passed regulation facilitating the pharmaceutical industry’s use of DTCA on 
television (Auton, 2006). Specifically, the FDA reinterpreted its existing regulations and 
changed how risk information was to be presented. Prior, all drug side effect information 
had to be reported but this reinterpretation allowed the amount of risk information to be 
proportional to the amount of benefits the drug listed in the advertisement, or what has 
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been dubbed a ‘fair balance’ between benefits and risks of the drug (Terzian, 1999). This 
new interpretation made televised DTCA much more feasible. 
 The situation in Canada has been somewhat different from that of the U.S. Direct to 
consumer advertising is technically illegal in Canada under the Foods and Drug Act 
(Mintzes, 2006). However, in 1978, an amendment to the act was passed stating that the 
name and price of Schedule F drugs can be advertised (Mintzes, 2006). In 1996 a policy 
paper was issued by Health Canada which clarified the Foods and Drugs Act. This memo 
defined what is considered advertising (Mintzes, 2006). The clause stated that 
advertising’s primary purpose is to promote sales. Together, this clarification in 1996 and 
amendment in 1978 has allowed many pharmaceutical companies and their advertising 
agencies to expand DTCA further than before should they so choose. This has resulted in 
two accepted forms of DTCA in Canada: educational, disease-awareness DTCA and 
reminder ads, where only the brand is mentioned (Mintzes, 2006).  
 
Direct-to-Consumer Advertising’s Effectiveness 
 The pharmaceutical industry continues to use DTCA because it is effective in its 
current form; otherwise, logically, spending on this promotional tool would not continue. 
In fact, investment in DTCA continues to grow. Since changes in FDA regulation have 
taken effect, the amount spent on DTCA has risen from 9% to 16% of total promotion 
spend (Morgan, 2007). In 2000, industry spend on DTCA was $2.47 billion compared to 
$1.07 billion in 1997 (Zachary, Dalen & Jackson, 2003; Rosenthal et al., 2002). In 
Canada, industry spending on DTCA was $22 million in 2006 compared to $2 million in 
1999 (Mintzes, Morgan & Wright, 2009).  
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 Aside from investment indicators of effectiveness, how do we know DTCA 
influences consumers? First, it is effectively reaching consumers. Indeed, the average 
American views sixteen hours of televised DTCA per year (Brownfield et al., 2004). In 
2000, it is estimated that 100 million consumers sought further information after seeing 
DTCA, 53 million individuals consulted their physician about a drug they had seen 
advertised and 12.1 million patients received the drug they requested from their physician 
(Holmer, 2001).  
 Finally, financial data shows DTCA impacts revenues. DTCA positively affects 
important measures such as brand share and particularly category sales (Wosinska, 2002; 
Narayanan, et al., 2004). In terms of ROI, the median return on investment (ROI) for 
every DTCA dollar spent is two dollars, with the greatest return being $6.5 on the dollar. 
In addition, between 1998 and 2003, 75% of drug brands that utilized DTCA as a 
marketing technique had positive ROI at or above $1.50 per dollar invested and 35% 
having a $2.50 return (Gascoigne, 2004). 
 Given the overall effectiveness that DTCA has on sales, some have questioned 
whether DTCA is providing an overall benefit to patients or rather biased information 
used solely to promote. There is heightened concern about bias in this form of advertising 
is particularly acute compared to other industries. As Frosch et al. (2007) states: “Poor 
judgment among soap brands may have few health consequences; DTCA’s influence on 
drug preferences…is a much more substantial concern for health care expenditures and 
population health.” (p 12). 
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Arguments For and Against DTCA 
 DTCA has proven to be a very controversial form of advertising. Researchers, 
media, academics, government, the pharmaceutical industry and other key stakeholders 
have presented data and arguments supporting their views of what they believe should 
ultimately happen with DTCA. Attitudes toward DTCA are indeed quite polarized 
(Auton, 2006), however there are those who advocate a compromise and argue for the 
middle ground.  
 
Arguments for Direct-to-Consumer Advertising 
 “After completing a thorough review of Direct-to-Consumer (DTC) prescription 
drug advertising, the National Health Council believes that DTCA advertising is an 
effective tool for educating consumers and patients about health conditions and possible 
treatments” (National Health Council, 2002a, b as cited in Calfee, 2002).  
 One of the main arguments put forward by proponents of DTCA is one that 
focuses, rightly so, on the patient. Patient empowerment, the right of the patient to 
actively participate in their own healthcare, is advocated by many (Stolberg, 2000; 
Anderson et al., 1995; Funnell, et al., 1991). Advertising in general provides information 
to consumers about a product and puts the purchase decision in their hands. Consumer 
empowerment is particularly important in pharmaceutical advertising as patients are not 
as informed as physicians (Calfee, 2002) and there are many diseases which are under-
diagnosed and under-treated such as depression (Glick et al., 2001), AIDS (Fleming et 
al., 2002), diabetes (Leape, 1995) and osteoporosis (Nguyen, Center & Eisman, 2004).  
 Advocates for DTCA also maintain that restricting consumer’s access to health 
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information implies the consumer is not intellectually equipped to participate in their own 
healthcare. Pro-DTCA individuals argue this is simply not the case and that patients are 
becoming active participants in their healthcare and are developing a high level of 
knowledge about medical issues (Singh & Smith, 2005).  
 Pro-DTCA individuals have cited evidence to back up their claim that patients are 
more than competent enough to receive health information via DTCA. Risk information 
is more important to consumers than benefits (Deshpande et al., 2004). A consumer 
survey released in 1999 by the FDA (as cited in Calfee, 2002) found that if a specific 
drug concerned them, 85% of consumers reported that they would read all or almost all 
information provided on a DTC ad for that drug (Calfee, 2002). A 2000 survey conducted 
by Prevention Magazine (as cited in Calfee, 2002), found that 37% of consumers report 
skimming the risk information summary presented in print DTCA (Calfee, 2002). 
 An additional argument to support patient empowerment is that consumers may be 
more critical and skeptical of DTCA than opponents of DTCA give them credit for. Data 
from the Prevention survey found that risk information made 36% of respondents less 
confident about taking the medication compared to 24% who felt more confident and 
34% who reported risk information as making no difference to them. In addition, a 1999 
FDA study found that 59% of consumers recognized there should be more risk 
information contained in DTCA, while only 49% stated there should be more information 
about drug benefits (Calfee, 2002). Echoing these surveys, Spake and Joseph (2007) 
found that 49% of consumers believe their doctors prescribing choices are influenced by 
the pharmaceutical industry, 69.5% of people believe that more DTCA regulation is 
needed and only 5.8% believe that the FDA properly regulates drugs. This evidence 
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suggests that consumers are critical enough of pharmaceutical advertising to quell critics’ 
concerns (Calfee, 2002). 
 In addition to providing consumers with an additional source of health education, 
proponents of DTCA argue that it allows patients to improve the dialogue and 
relationship with their physician. For example, approximately 75% to 81% of patients ask 
more specific questions to their physician during their next visit after seeing DTCA 
(Advanced Analytics Inc., 2004 as cited in Auton, 2006; FDA, 1999 as cited in Calfee, 
2002). Welch, Cline and Young (2005) argue that DTCA does not alter the patient-
physician relationship in a negative way. Rather, DTCA encourages patients to make 
drug inquiries to their physician without taking away relational control from the 
physician. Ninety-three percent of patients report that physicians welcome their questions 
ad 83% report their physician reacted to their questions as a normal part of their visit 
(FDA, 1999 as cited in Calfee, 2002). 
 Those in favor of DTCA argue that it does not inflate the cost of prescription drugs 
as critics have claimed. Rather, the retail price of drugs reflects how valued the product is 
to consumers, physicians and insurance payers (Rosenthal et al., 2002). In addition, some 
argue that advertising in general will decrease the cost of the item because advertising 
increases competition between brands (Calfee, 1997). Furthermore, research has 
demonstrated that there exists no correlation between the amount of DTC advertising and 
the cost of prescription drugs (Manning & Keith, 2001). 
 Fourth, supporters of DTCA argue against claims that while DTCA may not cause 
inflated drug costs, it most certainly increases prescription volume. Research has shown 
that there is no connection between the amount spent on DTCA and the percentage 
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increase in sales of these drugs (Manning & Keith, 2001; Calfee, Winston & Stempski, 
2002). 
 An added benefit of DTCA, proponents argue, is that DTCA causes individuals to 
focus more on their health in general rather than solely on prescription drug solutions to 
their medical problems (Calfee, 2002). Fifty-three percent of patients who approached 
their physician after seeing a DTC ad reported their doctor mentioned a non-drug therapy.  
Pharmaceutical companies are also beginning to stress a holistic approach to healthcare in 
addition to promoting pharmaceutical therapies. As part of their ‘More than Medication’ 
initiative, Pfizer recently released a phone application, Smidge, which aims to help 
consumers improve their overall health by helping them develop healthy habits (Pfizer 
news release, 2012).  
 Overall, proponents of DTCA focus on its educational value, its ability to improve 
the patient-physician dialogue and refute claims that it increases unwarranted prescribing. 
 
Arguments Against Direct-to-Consumer Advertising 
 Many arguments have been leveled against the pharmaceutical industry’s use of 
DTCA. The main rationalization behind those who are against DTCA is that the money 
could be better spent on advertising about health issues that promote the long-term health 
of society rather than indirectly funding prescription drug advertising that promotes the 
pharmaceutical industry’s agenda (Almasi et al., 2006; Avron, 2003). 
 Most critics point out that DTCA cannot be framed as a form of health education. 
Bell et al. (2000) systematically addressed this question by performing a content analysis 
of DTCA. They found that information commonly found in DTC ads are the condition 
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name and a few symptoms. They argue that this amount of information alone cannot be 
considered as providing educational value. In addition, even if DTCA is educational to 
some extent, its benefits will end once DTCA for a particular condition is no longer 
profitable for the pharmaceutical company doing the advertising (Almasi et al., 2006). 
Along similar lines, some research has questioned how DTCA can truly be informative 
and unbiased in its assessment of its product when the point of advertising is to persuade 
the consumer and sell a product (Poitras & Meredith, 2009). Finally, consumers may 
believe they are being informed through the information provided in DTCA and this may 
actually reduce their motivation to seek additional information about a disease or drug 
elsewhere (Almasi et al., 2006). 
 Another argument put forward against DTCA is that it does not present a fair 
assessment of the potential risks associated with the advertised drug (Herzenstein, Misra 
& Posavac, 2004). Critics argue that advertising backed by a profit-motive simply cannot 
be educational (Finlayson & Mullner, 2005). In an analysis of a DTC ad for Johnson & 
Johnson’s Cypher™, a sirolimus-coated stent, Boden and Diamond (2008) found that the 
number of possible adverse events presented in the ad was five compared to fifteen listed 
on the company’s website and 44 listed in a patient-education brochure about stents. 
Importantly, the ad did not mention the possible side effect of death, which is mentioned 
both on the website and brochure. 
 A third argument critics put forward against DTCA is its use of emotional appeals. 
Frosch et al. (2007) performed a content analysis of DTC ads presented during prime 
time television in order to determine the types of advertising appeals used. The 
researchers found that the ads presented incomplete symptom and prevalence information 
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while relying mainly on positive emotional appeals of regaining control of one’s life and 
gaining social approval. The authors argue that the use of these strong emotional appeals 
may cause consumers to disregard the little risk information that is presented within the 
ad. What effect might this have? Individuals who use DTCA as a reason to speak with 
their physician may be doing so based on positive emotional appeals and not for rational 
reasons. This argument is critical when one considers that people who take DTCA 
information they found to their doctor are more likely to be poor, less likely to be healthy 
and more likely to see their physician regularly (Murray et al., 2004). In addition, those 
who received the medication they saw in a DTC ad were more likely to have low levels 
of education, income and not be pro-active in seeking health information (Murray et al., 
2004). 
 Additionally, those against DTCA argue that DTCA does in fact interfere with the 
doctor-patient relationship. First, physicians do not appear to be in favor of DTCA. 
Survey results show that four out of five family physicians are not in favor of DTCA 
(Lipsky & Taylor, 1997; Mintzes et al., 2005). Kravitz (2000) illustrates the dilemma 
physicians face when DTCA enters into the examination room. It is entirely possible that 
DTCA acts as a springboard for correct diagnosis even if what the patient thinks she has 
is not indeed the correct diagnosis. Alternatively, if DTCA leads patients to come visit 
their doctor with a diagnosis and treatment plan already in hand and the physician is more 
concerned about patient satisfaction than correct treatment, this may lead to disastrous 
results. Additionally, physicians may be time crunched when they see patients and may 
therefore be overly receptive to what the patient believes their problem to be rather than 
relying on their own expertise (Pollack et al., 2009).  
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 In terms of health care costs, Poitras and Meredith (2009) argue that DTCA 
increases health care costs by increasing both prescribing volume and drug costs. 
Pharmaceuticals are one of the fastest growing costs of health care, increasing 15% per 
year (Angell, 2004). A congressional report showed that DTCA does in fact increase drug 
sales (Gottlieb, 2002). Indeed, in a survey asking health care payers, providers, patient 
groups, advertisers and pharmaceutical representatives whether they believed DTCA will 
increase the cost of prescription drugs, 80% responded yes, regardless of what industry 
they were in (Mintzes, Barer, Lexchin & Bassett, 2005). 
 Contrary to DTCA advocates, critics argue consumers do not have the requisite 
knowledge and are not equipped to make medical decisions and could therefore be 
creating inappropriate demand for prescription drugs (Spake & Joseph, 2007). The 
average consumer is not trained in medicine and should not be expected to understand the 
implications and risks of seeking out one particular drug, treatment regimen or drug 
brand over another (Almasi et al., 2006).  For example, Hoek and Grendall (2003) found 
that consumers have high recall for drug information reported in DTCA but much lower 
recall (20%) for risk information presented. In that study, 60% of respondents reported 
being confused about the risk/benefit information after viewing DTCA. 
 
Arguments for Regulation Revision of Direct-to-Consumer Advertising 
 “DTCA is neither good nor evil; it is both.” (Kravitz in Almasi et al., 2006 p0285). 
Although many actors within the DTCA debate are firmly convinced of its inherent 
shortcomings or virtues, some take a more balanced view. Richard Kravitz argues that 
DTCA plays a role in healthcare but must be regulated in order for the public to receive 
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the maximum benefit (Almasi et al., 2006).  
 Individuals in this camp favor a balance between the pharmaceutical industry’s 
innovation and First Amendment rights with the public’s need for protection against 
misleading advertising and inflated drug costs (Chin, 2005). Some acknowledge that 
DTCA may cause over prescribing of prescription drugs but also acknowledge that there 
is under-treatment and low awareness of certain medical issues (Almasi et al., 2006). 
Kravitz et al. (2005) investigated the issue of the potential for inappropriate prescribing 
based on patient requests stemming from DTCA. Antidepressants are one of the most 
heavily advertised drug categories. Kravitz and colleagues sent a confederate to various 
physicians while manipulating symptoms and request type. The symptoms presented 
were either suggestive of a diagnosis of adjustment disorder or major depression. The 
type of request was either for a branded medication, a general request for any medication 
or no request. They measured whether the physician wrote a prescription for the branded 
drug, any prescription drug or did not write a prescription. Results showed that while 
prescribing for adjustment disorder was lower than prescribing for the major depressive 
condition, branded drug requests seem to make more of a difference in prescribing for 
adjustment disorder. The branded drug in this study, Paxil, was prescribed in two thirds 
of cases where the confederate specifically requested Paxil and presented with adjustment 
disorder. Those presenting with major depression who made a drug request received a 
prescription 88% of the time, whereas those who did not received a prescription only 
65% of the time; a 23% difference. In comparison, physicians in the adjustment disorder 
condition prescribed medication 50% of the time, compared to 18% prescribing rate for 
those cases where the confederate made no request. That is a 32% difference. 
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Furthermore, general drug requests were just as effective at getting a prescription as 
branded drug requests. Importantly, there is no data to support prescribing 
antidepressants in adjustment disorder; but as based this study suggests, there is evidence 
that there may be widespread inappropriate prescribing for this condition when patients 
request any sort of medication for their symptoms during their visit. Overall, Kravitz 
argues that DTCA is beneficial for serious medical conditions and for those that need 
attention brought to them. However, drug inquiries stemming from DTCA for conditions 
that are not clearly defined may lead to inappropriate prescribing (Almasi et al., 2006). 
 
Consumer Attitudes and Behaviors toward Direct-to-Consumer Advertising 
 To obtain a more complete picture, one must also consider the consumer. How do 
they view DTCA and what are their attitudes toward it? 
 Consumers’ attitudes toward an ad are a commonly studied variable that is defined 
as consumer’s degree of favorableness or unfavorableness toward a given ad. Attitudes 
and consumer’s resulting behavior are intimately linked in the domain of advertising. The 
attitudes one holds toward a given advertisement has been linked to ones attitudes toward 
the brand and ultimately purchase intentions (MacKenzie & Lutz, 1989; MacKenzie, 
Lutz & Belch, 1986). 
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Consumer Attitudes Toward DTCA 
Research to date investigating the effects of DTCA from the consumer 
perspective has focused heavily on consumer attitudes and other antecedents of 
behavioral outcomes related to health care. This section will explore consumer’s attitudes 
toward their health, the pharmaceutical industry and specifically DTCA. 
 In general, consumers hold positive (Murray et al., 2004; Deshpande, 2004) to 
neutral (Wilkes, Bell & Kravitz, 2000) attitudes toward DTCA. In a study by the FDA 
conducted in 1999, respondents were in favor of seeing DTC ads at a ratio of two to one 
(Calfee, 2002). Consumers recognize that DTCA is an information tool. Eighty-six 
percent of participants surveyed by the FDA reported that DTCA helps them increase 
their awareness of new drugs. About 40% of consumers report that they factor DTCA 
into their medical decisions (Deshpande et al., 2004) whereas the 1999 FDA results show 
that only 47% on respondents agree that DTCA helps them make better informed 
decisions about their health (Calfee, 2002). However, 75% of FDA respondents stated 
that DTCA helps them have better discussions with their physician. 
 
Consumer Behavioral Response to DTCA 
 DTCA is the catalyst of many patient behaviors. For example, DTCA can lead the 
consumer to seek more information about a condition (Liu, Doucette, Faris & 
Nayakankuppam, 2005; Sumpradit, Fors & McCormick, 2002; Doucette & Schommer, 
1998) and it is widely accepted that DTCA can motivate individuals to visit their 
physician (Lehrer et al., 2000; Slaughter & Schumacher, 2001; Weissman et al., 2003) 
and even request a drug from their physician (Peyrot, Alperstein, Van Doren & Poli, 
29 
1998). 
 Certain demographic and health related factors increase DTCA’s influence on 
consumer’s subsequent behavior. For example, low socioeconomic status, illness (Murray 
et al., 2004) and gender (Bell et al., 2000) all play a role in the net effect DTCA has on 
consumer behavior. 
In addition to demographic factors, certain attitudinal variables also impact the 
effect DTCA will have on the consumer. Herzenstein et al. (2004) analyzed secondary 
data collected by the FDA. They investigated whether consumer’s general attitudes 
toward DTCA result in behavioral consequences such as searching for additional 
information, asking a physician about the drug and the likelihood of receiving a 
prescription. Holding positive attitudes resulted in a higher likelihood of consumers 
searching for additional information about the advertised drug and asking their physician 
about the drug. Interestingly, results also showed that consumers’ positive attitudes 
increased the chances of them asking their physician about the drug and also receiving a 
prescription. Similarly, Spake and Joseph (2007) surveyed consumers and found that 
believing DTCA is informative and adequately reports side effects predicted consumers’ 
willingness to meet with a physician and request the advertised medication. 
Although there is a growing understanding of consumer’s attitudes and behaviors 
toward DTCA, there exists a gap in this literature on consumer’s cognitive processing of 
the information they are presented within DTCA and how this may impact consumer 
behavior. 
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BIASES IN SELF-PERCEPTION AND BEHAVIORAL PREDICTION 
 
 Social science researchers have been studying an enigma seemingly inherent to the 
human species for many decades. This enigma, simply put, is that people are reasonably 
good at assessing the skills and performance of others yet self-assessment seems 
exponentially more difficult. Individual’s perceptions of their own skills and abilities 
only ever correlate weakly with objective performance measures (Ehrlinger et al., 2008). 
Adolescent men’s’ confidence in their knowledge about condom use correlates very 
weakly with their objective level of knowledge (Crosby & Yarber, 2001). In the health 
domain, even physicians in a domain they should be highly familiar with fail to 
accurately assess their own knowledge on the topic (Tracey et al., 1997).  Finally, in a 
meta-analysis of the correlation between objective ability and perceived ability, Mabe 
and West (1982) found a .29 correlation between the two variables. Although this level of 
correlation is far from perfect, there very rarely is a perfect correlation. However, when 
considering how much more accurately people are able to assess the abilities and 
strengths of others, this weak correlation becomes surprising. Individuals are much more 
accurate at predicting the behavior of others. For example, surgical resident’s self-
assessment of their behavior does not predict their performance on their board exams, but 
their peer’s assessment does (Risucci, Tortolani & Ward, 1989).  
 How can this paradox be explained? What are the causes of individuals’ less than 
stellar ability to judge their abilities in both social and cognitive domains? Why are 
perceptions about other’s abilities so much more accurate? This manuscript will focus on 




 Individuals are overly optimistic in many areas of life. Within the psychological 
literature, this phenomenon has been termed ‘unrealistic optimism’ and may be one of the 
underlying causes of people’s inability to accurately assess their own skills and abilities.  
 Unrealistic optimism is pervasive particularly within the health domain. Weinstein 
(1987) conducted a survey investigating the degree to which respondents believed they 
were at risk of 32 health-related problems including, for example, the probability of 
developing a drinking problem, gallstones, diabetes, stroke, cancer, etc. Participants were 
asked to rate the likelihood of falling victim to these hazards compared to others their 
age. Results showed that across age, sex, education and occupation categories, 
respondents systematically underestimated the probability of having a negative health 
event happen to them. This bias also results in negative behavioral outcomes. For 
example, people believe themselves to be less prone to catching the flu than the average 
person and therefore are less likely to get a flu shot (Larwood, 1978). 
 There are many components to individuals’ unrealistic optimism. In addition to 
believing they are less at risk for negative events, people also believe the probability that 
they will experience positive life events is high.  
 Another behavioral consequence of unrealistic optimism is it also causes 
individuals not only to look on the bright side, but to be overconfident in those often 
inaccurate judgments and predictions. Indeed, when a group of physicians diagnosed 
patients as having pneumonia, predictions that were made with 88% confidence were 
only correct 20% of the time (Christensen-Szalanski & Bushyhead, 1981).  
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The Above-Average Effect 
 One type of self-serving assessment deals with how individuals assess their own 
abilities relative to their peers. The above-average effect occurs when individuals believe 
themselves to be above average in most areas of life, which is of course mathematically 
impossible (Alicke & Govorun, 2005). 
 On the whole, it is quite common for individuals to make self-serving appraisals of 
their performance across many domains. It is hypothesized that such self-serving 
assessments are indeed adaptive and are in place to preserve one’s sense of self-esteem. 
The lack of these biased self-assessments are associated with feelings of helplessness and 
depression (Alloy & Ahrens, 1987; Taylor & Brown, 1988).  
 These types of self-serving biases are facilitated by the lack of objective standards 
for many classes of behavior (Dunning, Meyerowitz & Holzberg, 1989). Lacking these, 
individuals are free to pick and choose those criteria, which put them in the top ranks of a 
given skill set. It is an open question whether the preservation of self-esteem, is caused 
by discounting evidence that goes contrary to non-desired outcomes (Gilovich, 1983; 
Kunda, 1987, Lord, Lepper & Ross, 1979), or on the availability heuristic (Tversky & 
Kahneman, 1974). Either way, it has been shown experimentally that individuals often 
select attributes of a quality that are most in line with their strengths and disregard other 
characteristics of that quality which may lower perceptions of their ability (Weinstein & 
Lachendro, 1982). When an individual has to use a static set of criteria to judge their 
capabilities compared to others, overestimation of their ability drops dramatically 
(Dunning et al., 1989).  
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Base Rate vs. Dispositional/Case-Based Judgments: Predicting Behaviour 
 In addition to inaccurate self-perceptions of ability, individuals also poorly predict 
their own future behavior. People typically focus on case-based, or dispositional 
information, and disregard distributive, or base-rate information, when performing self-
assessments. In contrast, people are less biased when assessing others and because they 
use both types of information, resulting in a more accurate judgment (Kahneman & 
Tversky, 1979; Epley & Dunning, 2006).  
 In addition to largely failing at predictive judgments due to utilizing the incorrect 
information as with self-perceptions, individuals tend to be overconfident in those 
behavioral judgments as well. Dunning, Griffin, Milojkovic and Ross (1990) investigated 
this issue by asking participants in their study to make predictions as to an individual’s 
future behavior in a given situation and varying the level target subjects were 
individuated. Importantly, they found that the more a subject’s predictions went against 
the base rate for the behavior in question, the more often subjects are wrong in their 
prediction and the more overconfident they are. The authors show that people are more 
overconfident when they base their prediction on dispositional or case-based information 
and are actually slightly underconfident when predicting in the same direction as base-




 One avenue open for investigating how consumers’ cognition relates to DTCA is 
assessing their level of metacognitive ability. Individuals who lack knowledge and 
expertise in a given area are at a disadvantage when making self-assessments. In addition 
to being overly optimistic, they also lack the ability to know how poorly they are 
performing at the task. In order for an individual to know they are performing poorly, 
they must have at least some basic knowledge of the area in order to recognize their 
incompetence. The term for this skill, the ability to monitor one’s own thinking and 
knowledge processing is called metacognition. Metacognition can be defined in many 
ways. For the purposes of this thesis, metacognition will be defined as the ability to think 
about one’s own cognitive processing (Flavell, 1979). To illustrate this definition, it is 
helpful to review the work by one of the pioneers of metacognition. In a study comparing 
the metacognitive ability of preschool and elementary school children, Flavell, Friedrichs 
and Hoyt (1970), asked children to study a set of items until they were positive they 
would be able to recall the items perfectly. Older children were typically ready for the 
recall task once they said their study of the items was complete. However, the younger 
preschool age children usually were not ready for the recall task when they reported they 
had completely memorized the list of items. The implication here is that older children 
are better able to monitor the state of their own knowledge and understanding and thus 
would be categorized as having superior metacognitive ability than younger children. 
 Research has demonstrated that all individuals, regardless of age or ability, lack 
self-insight to some degree and find it difficult to produce accurate self-assessments. 
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However, those with low knowledge in a given domain seem particularly at risk of 
producing self-assessments that do not coincide with reality (Ehrlinger et al., 2008; 
Kruger & Dunning, 1999).  
 
Consumer’s Metacognitive Ability and DTCA 
 In addition to investigating consumer’s attitudes and behaviors stemming from 
DTCA, a few researchers investigating consumer behavior in relation to DTCA have 
demonstrated some interesting findings related to human cognition, specifically the role 
of the consumer’s perceived knowledge.  
 Maddox and Katsanis (1997) surveyed consumers to determine how DTCA impacts 
the patient-physician relationship. They found that whether subjects were told the source 
of information about a new drug was DTCA or a physician had no effect willingness to 
seek additional information about the drug. In addition, the authors found that while 
consumers have little worry about discussing a prescription drug they have seen 
advertised, those who have seen DTCA are less likely to have discussions about, and seek 
out information regarding, advertised drugs. The authors suggest that DTCA may be 
inadvertently increasing consumer’s confidence in their knowledge and thus do not feel 
the need to retrieve new information. 
 Hoek and Maubach (2007) conducted a survey of New Zealand consumers to 
determine whether DTCA has the educational effect proponents argue it has. The authors 
investigated whether DTCA merely bolsters feelings of self-efficacy among consumers. 
The authors predicted that if DTCA were serving an educational function, consumers 
with little medical knowledge would be more likely to appreciate the information and 
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therefore view DTCA more positively than consumers with high levels of medical 
knowledge. Based on their findings, the authors suggest that rather than educating or 
motivating consumers to seek more information, DTCA may just be bolstering the self-
efficacy among those with insufficient medical knowledge. 
 Much research has investigated how attitudes toward DTCA influence consumer’s 
interaction with their physician. Results have been mixed with some research concluding 
positive attitudes have little to do with drug inquiry intentions (Perri & Dickson, 1988; 
Williams & Hensel, 1995) while others find a positive relationship (Deshpande, et al., 
2004; Herzenstein et al., 2005; Peyrot et al., 1998; Singh & Smith, 2005). An (2007) 
attempted to reconcile these conflicting findings by proposing consumer’s perceived 
knowledge as a moderator. The investigation entailed determining how consumer’s 
attitude toward DTCA and perceived knowledge of medical issues influenced their 
intention to ask or insist their physician prescribe them a medication. Respondents were 
sampled by phone and were asked their general attitudes toward DTCA, how 
knowledgeable they feel themselves to be about health and medicine and how likely they 
would be to request a drug or insist on a prescription for a specific drug from their 
physician. Results indicate that consumer’s perceived health knowledge significantly 
bolsters the relationship between attitude toward DTCA and drug inquiry intentions. 
 An’s (2007) study lays the groundwork for further inquiry into how consumers 
cognitive processes, particularly their understanding of their own knowledge, relates to 
DTCA and the patient-physician relationship. However, there are some areas in which 
this research could be improved upon. Methodologically, An’s measure of consumer’s 
concept of their own knowledge of medical issues is a single item which has not been 
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validated in other research. Second, the study is unable to parse whether actual or 
perceived health knowledge influences drug inquiry intentions. Conceptually, what An is 
referring to in her research as ‘perceived knowledge’ can be better categorized under an 
existing branch of literature within the domains of cognitive psychology and cognitive 
neuroscience known as metacognition, discussed above. 
 
THE UNSKILLED/UNAWARE HYPOTHESIS 
 
To determine whether one’s level of knowledge and metacognitive ability can 
cause inaccurate self-assessment, Kruger and Dunning (1999) investigated whether 
accuracy of self-assessment varies across individuals for given domains based on their 
level of metacognitive ability. Answering this question, they argue, sheds light on why 
individuals who are unskilled within an area are also the worst at evaluating their own 
performance. Kruger and Dunning (1999) demonstrate across a variety of tasks that 
participants who score in the bottom quartile of ability within a domain consistently and 
drastically overestimate how well they scored on an objective test compared to those who 
score in the top half of the distribution. They also demonstrate that this is likely due to 
insufficient metacognitive skills these participants have within that domain. The author’s 
operationalized metacognitive skill as the ability to recognize competence within a 
domain, be in the participants or another individuals. They demonstrate this effect and are 
also able to reverse it. As predicted, when subjects were taught the basic knowledge 
required to become proficient within a domain, their metacognitive ability and accuracy 
of self-assessment improved as well. 
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 Kruger & Dunning’s (1999) results have sparked debate about why those who lack 
skills consistently assess their performance inaccurately. Some have argued that Kruger 
& Dunning’s (1999) pattern of results could be explained due to regression to the mean 
and the unreliability of measures assessing participants’ objective level of performance. 
Krueger and Mueller (2002) argue that these two factors reduce the strength of the 
correlation between objective and perceived task performance. In addition, others have 
argued that using a comparative measure to assess participant’s perceived performance is 
not reliable, as everyone finds comparative judgment difficult regardless of their level of 
expertise within a particular domain (Burson, Larrick & Klayman, 2006). In other words, 
trying to assess one’s performance compared to others is inherently difficult. In addition, 
Kruger and Dunning’s (1999) measures assessing a given skill set were accused of being 
too simplistic. Burson et al. (2006) argued that everyone, regardless of ability, would 
perceive a test as being simple when it is and therefore everyone will report superior 
performance, but only those with top ability will be correct. 
Ehrlinger et al. (2008) addressed these concerns in a series of studies demonstrating 
that Kruger & Dunning’s (1999) pattern of results hold when correcting for statistical 
unreliability, when using ecologically valid measures of objective performance and 
including both comparative and non-comparative measures of perceived performance.  
Another major concern regarding Kruger & Dunning’s (1999) findings was that 
participants, particularly those who perform poorly on the task, will be highly motivated 
to preserve a positive self-image and may try to save face by drastically overestimating 
how well they performed. Those who found the task easy will also feel this self-image 
pressure, but their estimates of perceived performance will be accurate. To address this 
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alternative explanation, Ehrlinger et al. (2008) include conditions where they provide 
monetary incentives for participants to accurately report their performance, including a 
study where undergraduates were afforded the chance to win $100 if they could 
accurately report how many questions of logic ability they answered correctly (Ehrlinger 
et al. 2008, Section 2, Study 4). No participant was able to come close to this objective, 
despite the authors’ assumption that $100 is incentive enough for the average 
undergraduate student to put aside concerns of image. Ehrlinger et al. (2008) address the 
motivation argument by using social incentives as well. In one of their studies, the 
authors introduce an ‘accountable’ condition where subjects are told they will have to 
provide an explanation to a supervising professor about their rationale for their self-
assessment of their performance. Even with this social pressure, low performance 
individuals do not become more accurate in their self-assessment. In fact, participants 
became more confident of their inflated self-assessment. 
 
Summary 
 Consumers searching out health information continues to increase. Consumers seek 
out or encounter health information from multiple sources including websites, print 
sources, physicians and friends and family (Eysenbach & Kohler, 2002; HSC Community 
Tracking Study Household Survey, 2001; HSC Community Health Tracking Household 
Study, 2007).  
 This behaviour may be, in part, due to the increased availability of health 
information for the average consumer and has possibly led to the medicalization of issues 
that were previously outside of the healthcare industries purview.  
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 DTCA is often cited as a potential source of overmedicalization (Healy, 2004; 
Poitras & Meredith, 2009; Pollack et al., 2009). However, the exact mechanism of action 
between the consumer viewing DTCA and prescriptions being written is unclear. 
 Much research demonstrates that individuals are very poor at making self-
assessments, both of their knowledge and predicting their own behavior. One possibility 
is that consumers are taking information gleaned from DTCA and overestimating just 
how qualified they are to make health care decisions. 
  This research attempts to clarify how and if consumers viewing DTCA may 
increase feel more knowledgeable about healthcare issues and if so, whether that feeling 
of increased skill translates into potentially unnecessary visits to the physician.  
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THEORETICAL MODEL AND HYPOTHESIS 
DEVELOPMENT 
 
Consumers with low levels of knowledge suffer the dual burden of insufficient 
knowledge to be proficient in a given domain and low metacognitive ability such that 
they are unaware of their lack of proficiency. This research will extend this general 
finding to determine whether this behavior holds in the healthcare context. Next, the 
study measures what effect DTCA has on one’s metacognitive ability. Lastly, these 
findings will be put into context by measuring what effect all of this has on drug inquiry 








DEVELOPMENT OF H1 
 
 Based on Kruger & Dunning’s (1999) unskilled/unaware theory, patients with high 
levels of knowledge of a particular disease may be more likely to have high levels of 











Fig 1. Proposed theoretical model tested in this research 
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metacognitive ability; and therefore, are better able to make more accurate self-
assessments of their ability. Contrary, patients with a low level of knowledge should 
suffer from the inverse.  
 Without the ability to recognize their knowledge about a given disease is limited, 
low disease knowledge consumers may be more likely to believe they are well-equipped 
to communicate with their physician about drugs in this category. Therefore, the 
following hypotheses were proposed: 
 H1a: Consumers with a low level of disease knowledge will be more likely to 
 intend to communicate with their physician about a drug than high knowledge 
 consumers. 
 H1b: Consumers with a high level of disease knowledge will be less likely to 
 intend to request a drug from their physician than low knowledge consumers. 
 
DEVELOPMENT OF H2 
 
 Consumers who possess high levels of disease knowledge should have the 
metacognitive skills to put their level of knowledge in perspective. The well-informed 
patient should understand that their physician is better informed than they are about 
current medications available for the treatment of depression. An (2007) found that 
consumer’s drug request intentions were much lower than their drug inquiry intentions. 
This may be due to the fact that most consumers have enough general knowledge about 
health issues such that they have the ability to realize their physician has been educated in 
medicine and therefore feel intimidated making a direct drug request. 
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 The inverse of the relationship between knowledge and drug request should be true 
for low knowledge patients. Consumers who have low levels of knowledge likely feel 
more confident in speaking to their doctor about a drug due to low metacognitive ability. 
Those who hold positive views of DTCA are more likely that those who hold negative 
views to request the advertised drug from their physician (Deshpande et al., 2004; 
Herzenstein et al., 2004; Peyrot et al., 1998; Singh & Smith, 2005). It is possible that 
those who hold positive views do so because they lack the knowledge to be critical of the 
information that is being presented to them in DTCA. Given the aforementioned reasons, 
the following hypothesis is tested in this study: 
 H2: Consumer’s level of domain-specific metacognitive ability will partially 
 explain the negative relationship between level of knowledge about a disease 
 and intention to communicate with a physician. 
 
DEVELOPMENT OF H3 
 
 Next, what role does DTCA play in this? Consumers may be less likely to initiate 
in-depth discussion with their physician or seek additional information about a drug after 
viewing DTCA (Maddox & Katsanis, 1997). One reason for this may be that DTCA 
bolsters patient’s self-confidence. In addition, Hoek and Maubach (2007) postulate that 
DTCA may be increasing consumer’s feelings of self-efficacy or self-confidence. Based 
on this, it is possible that DTCA will act as a moderator between the individual’s 
objective level of knowledge and level of metacognitive ability. Specifically, DTCA will 
intensify the positive correlation between objective knowledge of the disease and 
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metacognitive ability. In other words, consumers with low levels of knowledge will be 
even more inaccurate in their assessment of their disease knowledge compared to those 
who do not see the DTCA. 
 
  H3a: Low disease knowledge consumers who view a DTC ad will have lower 
 metacognitive awareness than low knowledge consumers who do not view a 
 DTC ad. 
 H3b: High disease knowledge consumers who view a DTC ad will have 
 metacognitive awareness that does not significantly differ from that of high 










 Participants were recruited to complete this study via Canadian Viewpoint’s 
(Canview) web-based subject panel. Canview recruits subject pool participants from a 
variety of backgrounds across Canada. Panel members are sent invitations to participate 
in the survey. If they accept CanView’s terms, they are directed to an online platform 
hosting this survey. Subjects then have to accept the terms of the study after reading the 
consent form. Subjects who reported presently being treated for depression or taking 
medication for depression were excluded.  
 
Pretest Sample 
 To determine the validity and reliability of the questionnaire, a subsample of 
participants (n=50) were administered the survey. Thirty-seven males and 13 females, 
with a modal age of 25-44 years old participated.  Their mean level of socio-economic 
status was 43.5, or medium business, technical class.  
 
Main Sample 
 Once the validity and reliability of the questionnaire were established, the 
remaining participants were tested. Pretest participants completed the same procedure as 
main sample participants. As pre- and main- sample demographic characteristics were 
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similar across groups, samples were collapsed for a total of n = 377. The final sample 
consisted of 217 males and 160 females with a modal age of 45-64 years old. Their level 






 The platform used to develop this questionnaire is a Canadian-based company 
called FluidSurveys. This software allows the researcher to program the questionnaire 
and subsequently publish it online.  
 
Knowledge About Depression 
 It was important to the theoretical model being tested in this study to be able to 
parse the influence of how much subject’s actual versus perceived knowledge influences 
intention to communicate or request a drug from a physician. The measure that was thus 
needed was one that tests a layperson’s objective level of general knowledge about 
depression. Such a measure, which balances technical and general knowledge, did not 
exist. Therefore, two surveys of depression knowledge were combined and adapted in 
order to create an appropriate measure. This measure was created in consultation with a 
practicing psychologist at a major teaching hospital. The first knowledge test chosen was 
Eli Lilly’s depressionhurts.ca ‘Understanding Depression’ questionnaire. The 
‘Understanding Depression’ questionnaire focuses strongly on knowledge about 
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depression symptoms and was adapted from American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR). The second 
knowledge test chosen to create the measure was the National Alliance on Mental 
Illness’s (NAMI) Depression Knowledge Quiz. This quiz is composed of seven questions 
which touch on symptoms, the ontogeny of the disorder, treatment etc. These two quizzes 
were merged to strike a balance between pharmaceutical industry and public interest 
groups perspectives on what constitutes ‘general knowledge’ about depression. 
 
Metacogitive Ability 
 In order to test participant’s metacognitive ability, what will be referred to as 
Kruger & Dunning’s (1999) ‘unskilled-unaware measure’, was used. The particular 
measure was used specifically in their Study 2 looking at participant’s logical reasoning 
ability and was emailed to the researchers by Dunning. This measure has also been used 
in various forms in many other publications (Burson, Larrick & Klayman, 2006; 
Ehrlinger & Dunning, 2003; Ehrlinger, Johnson, Banner, Dunning & Kruger, 2008; 
Dunning, Meyerowitz & Holzberg, 1989). The measure asks individuals to rate their 
performance relative to peers in terms of domain-specific as well as test-specific 
capacities. Domain specific questions ask participants to compare their level of general 
knowledge to others while test specific questions ask participants to compare their 
performance on this specific test to others. In these comparative questions, subjects are 
asked to rank their performance relative to their peers. This measure of metacognitive 
ability also includes a non-comparative item. This final question asks participants to 
estimate their raw score on the knowledge test.  
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Drug Request Intentions 
 The dependent measure of the model, participant’s intentions to communicate and 
request a drug from their physician, was critical in order to make findings of this research 
relevant for the pharmaceutical industry and regulators alike. The ‘Intended 
Communication Behavior Scale’ developed by Young, Lipowski and Cline (2005) was 
chosen to measure this variable. Prior to the development of this measure, many 
researchers had used single point measures to determine participant’s drug request 
intentions (Perri & Dickson, 1988; Williams & Hensel, 1995; Bell, Kravitz & Wilkes, 
1999).  
 This scale was developed based on past research and direct communication with 
twenty individuals. These individuals informed researchers about the ways they believed 
they would approach their physician about a drug they had seen advertised. This method 
resulted in a 7-item measure with an 11-point scale ranging from not at all to extremely 
likely. The measure was replicated in this questionnaire save for the number of scale 
items, which were reduced for brevity.  
 
Stimuli 
In order to determine whether DTCA may bolster feelings of perceived 
knowledge, an altered print DTC ad for depression was inserted into the questionnaire to 
enhance the validity of the findings rather than simply having subjects recall a DTC ad 
they had seen in the past. 
The decision was made to use a print rather than a video DTC ad similar to one 
that would appear on television for two reasons. First, the use of a print ad allows for 
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better control and this way, every participant is exposed to the same image. Conversely, 
using a video ad, it cannot be guaranteed that each participant would give equal amounts 
of attention to the ad. The print DTC ad is less dynamic and better ensures each 
participant processes the same information. Second, in order to preserve the realism of 
the ad, altering a print ad was more conducive to this goal than a video DTC ad. 
 The condition chosen for the DTC ad had to be one that affects a large population 
to be as relevant to as many study participants as possible. In order to limit responder 
fatigue, a single medical condition and ad were used to test the hypotheses. Depression 
was chosen because it is a condition that affects both younger and older populations 
roughly equally and an estimated one in ten Americans (Centre for Disease Control, 
2008) and approximately 6% of the Canadian population currently suffers from 
depression (Stephens, Dullber & Joubert, 1999). Depression tends to be more prevalent in 
women than men, but is also a serious concern for men as it is more likely to result in 
suicide for this sex than women (NIMH, 2007). Therefore, depression is a condition that 
is highly relevant to the sample. Second, it was important that the condition chosen for 
the ad was one that is advertised by the pharmaceutical industry in reality. Findlay (2001) 
found that in 1998 and 1999 an antidepressant drug (Paroxetine) was one of the top 24 
most heavily advertised. In fact, DTCA is focused on few therapeutic categories among 
the vast number possibly treated by pharmaceuticals. The top therapeutic categories 
advertised by the pharmaceutical industry include: anti-arthritics, cholesterol reducers, 
anti-ulcerants, anti-histamines, anti-asthma drugs and anti-depressants. Given this 
information and the knowledge that psychological disorders affect a large portion of the 
population, depression was the best choice of therapeutic category for this study.  
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 In order to create a DTC ad for depression, a real DTC ad was modified. The 
chosen print ad was AstraZeneca’s Seroquel XR (quetiapine fumarate) for the treatment 
of bipolar disorder and schizophrenia. This ad appeared in People Magazine beginning in 
December 2009. This ad was chosen for several reasons. First, the person in the image is 
female (representing those most diagnosed with the disorder). Second, this is a multi-
page ad, which reflects the reality of how many ads are shown in magazines. Third, the 
expression of the individual in the ad is displaying sadness, which is most in line with 
one of the top-of-mind symptoms of the therapeutic category. Fourth, the ad was had not 
been in print for some time.   
 The Seroquel XR ad was modified using Adobe Photoshop CS4 Extended 
Version 11.0 for Mac. The brand name was changed to ‘Zenalux’. Zenalux is a 
biomedical company located in Durham, North Carolina. Many names were considered 
and this name was chosen due to its ambiguity yet similarity to many drug brand names. 
The main colours of the ad were changed due to their strong association with the 
Seroquel XR brand. Additional information was integrated into the modified ad. 
Symptoms of depression as well as information of the neural mechanism underlying 
depression were added. Symptoms of depression were added for two purposes: (1) to 
substitute the large type found on the original Seroquel XR ad, and (2) generic symptom 
information was common in other print DTC ads for depression. Therefore, a symptom 
checklist found in an antidepressant ad, Pfizer’s Effexor XR (venlafaxine HCl) was 
placed in the ad. Again drawing from Effexor advertising, this time from their website 
(http://www.effexorxr.com/effexor-xr-treatment.aspx), information about the neural 
underpinnings of depression as well as a diagram of neurotransmission were added. This 
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was added in order to give participants added information about depression and give the 
ad more visual appeal. 
 
Control questions 
 An individual’s SES is a predictor of many health-related issues. For example, a 
person’s educational background is a predictive factor of cardiovascular risk (Winkleby, 
Jatulis, Frank & Fortmann, 1992). Those with low education and income bring forward 
more new reports of depression over a nine-year period compared to individuals with 
higher education and income (Kaplan, Roberts, Camacho & Coyne, 1987).  Given this 
evidence, participant’s SES acted as the main control variable in this study. 
 There is no one established measure of socio-economic status. However, 
Hollingshead’s (1975) four-factor index of social status is commonly used. The original 
measure collects the SES of a given individual or household by measuring (1) gender, (2) 
marital status, (3) educational attainment and (4) occupation. For married individuals, 
resulting scores for the two people are summed and divided by two to determine the 
nuclear family’s level of SES. For the purposes of this study only the individual’s SES 
was required therefore the marital status item was removed from the scale.  
 
Exclusion criteria 
 Potential survey respondents who have been diagnosed with, or are being treated 
for, depression were excluded from the data. Prior research has shown that patients with a 
condition are much more involved with healthcare decision-making (Arora & McHorney, 
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2000) and likely pay more attention to information presented and place more effort on 
comprehension (Celsi & Olson, 1988) than the average viewer.  
  
Procedures 
 Canadian Viewpoint first sent an invitation to members of their panel. Survey 
participants first agreed to the terms and conditions set forth by Canadian Viewpoint. 
Once they agreed, participants were then redirected to the survey site, hosted by 
FluidSurveys. As soon as the participant arrived at the study website, they were presented 
with the consent form approved by the Concordia University Office of Research Ethics 
for this study. Participants were asked to read the consent form and check a box at the 
bottom of the page to indicate their understanding of the terms as well as their freely 
agreeing to participate. Participants could not continue with the survey without checking 
this box.  
 Once consent was obtained, participants were then asked to complete screening 
questions, including ones related to history of depression, age and gender. If participants 
indicated that they are currently being treated for depression or fell into an age or gender 
category that had already reached its quota, they were redirected to the debriefing page. 
In all other cases, the participants were moved on to the following page. After ensuring 
the participant met eligibility criteria, they saw general instructions of what is expected of 
them for each section of the survey. 
 Next, participants were asked to complete the depression knowledge test (see 
variable measures section for details). Subjects were not timed during this section and 
therefore had time to try and answer to the best of their abilities. Those in the 
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experimental group saw the DTC ad. Subjects had 60 seconds to review the contents of 
the ad. After 60 seconds, the ad was removed from the screen. After viewing the ad, 
experimental subjects were asked to complete the measure of metacognitive ability, 
Dunning & Kruger’s (1999) ‘unskilled-unaware measure’. The survey was programmed 
such that age and gender information recorded at the beginning for each participant were 
piped into this section so that subjects had a clear reference group with whom to compare 
themselves. The order in which the questions of this measure were presented was 
randomized across participants. Participants were then asked to complete the ‘Intended 
Behavior Communication Scale’. Once this section was completed, participants 
responded to follow up and manipulation check questions. Finally, participants were 
automatically redirected to the debriefing form where an in-depth description of the study 






Normality Assumption Check 
 Each variable was tested in order to ensure assumptions of normal distribution 
were met (Appendix A). Each variable met this assumption; therefore, they were used in 
subsequent analyses without transformation. 
 
Manipulation Check 
 In order to ensure that those participants who were randomly assigned to the test 
group (n=178) were paying attention to the ad shown, a series of manipulation check 
questions were asked regarding the content of the ad. Based on the results, participants 
were paying attention to the contents of the ad shown. The vast majority of subjects 
correctly answered questions about the name of the drug advertised (79% correct), the 
gender and age of the model featured in the ad (93% correct), as well as the condition 






Fig 2. Results of manipulation check 
 
Factor Analysis of the Intention to Communicate with Physician Scale 
 A factor analysis of the Intention to Communicate with Physician scale was 
undertaken in order to validate the scale being used in this context. Although the ICB 
scale was most appropriate for this study, it was initially validated only informally by 
Young, Lipowski and Cline (2005). They validated this scale by interviewing individuals 
familiar with the topic. In addition, other measures also considered for measuring this 
variable had only one item. Therefore, the current analysis was performed in order to 
56 
confirm whether these types of single-item measures are in fact appropriate or whether a 
more comprehensive measure such as the ICB scale is required.   
 A principal component analysis with varimax rotation was conducted on the 
seven items composing the ICB scale. Results showed that only the first factor was 
needed to explain variation of this variable (Eigenvalue = 4.55, 65.006% of variance 
explained). Therefore, in subsequent analyses, the ICB variable was tested using only the 
results from the factor analysis. In addition, other rotation types were conducted 
(quatramax, equimax and promax) to validate the varimax rotation results. Using these 
other rotation methods did not alter results (Appendix B). 
 




MAIN ANALYSES – MODEL AND HYPOTHESIS TESTING 
 
 Overall, subjects overestimate their performance. Indeed, performance is 
overestimated regardless of whether subjects do so comparatively or independently of 
comparasons with others. When subjects  were asked to estimate their raw test score (out 
of 11), they overestimated by 2.22 points (t=-17.417, p<.000). 
 
Fig 4. Raw score and perceived raw score for total sample 
 
 Subjects significantly overestimated their generally ability when comparing their 
knowledge to others by 5.7% (t=-5.274, p<.000) and comparing their test specific score 




Fig 5. Comparison of test scores (total %) compared to estimated percent score on test 
and general depression knowledge compared to others. 
 
 Previously reviewed literature indicates that individuals tend to overestimate their 
performance in most areas. The aforementioned results are in line with that finding. 
However, the unskilled/unaware hypothesis (Dunning & Kruger, 1999) states that it is the 
individuals with the lowest amount of actual knowledge will most drastically in 
overestimate their performance compared to more knowledgeable individuals. Following 
Kruger and Dunning’s procedure, subjects were grouped into quartiles based on actual 
depression knowledge test performance.  A series of ANOVAs were conducted in order 
to determine whether there were significant differences between these depression 
knowledge ability quartile groups in terms of how well they were able to predict their 
actual performance. In order to do this, difference scores were created for each subject. 
Difference scores were created by subtracting the actual score from the estimated score. 
Actual versus perceived depression knowledge test scores 
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Fig 6. Difference scores of estimated and true raw score by quartile group  
 
 The first ANOVA that examined differences in estimated raw score by quartile 
group demonstrates that there are differences among groups (F=27.247, p<.000). The 
Bonferroni post-hoc comparison method, that the bottom quartile group significantly 
overestimated their score compared to all other groups. The top quartile was also 
significantly more accurate at self-assessment than the other groups. Although the second 
and third quartiles were not statistically significant from one another, they followed the 
general pattern of the theory-based trend and were significantly different from the top and 






Table 1. Results of the Bonferroni post hoc test for difference score comparisons across 
knowledge test score quartile groups 
Multiple Comparisons 
Dependent Variable: Difference Score MCAR and Raw  
 Bonferroni 




















2 .91* .325 .032 .05 1.77 
3 1.57* .326 .000 .71 2.44 
4 2.86* .326 .000 2.00 3.73 
2 
1 -.91* .325 .032 -1.77 -.05 
3 .66 .325 .253 -.20 1.53 
4 1.95* .325 .000 1.09 2.81 
3 
1 -1.57* .326 .000 -2.44 -.71 
2 -.66 .325 .253 -1.53 .20 
4 1.29* .326 .001 .42 2.15 
4 
1 -2.86* .326 .000 -3.73 -2.00 
2 -1.95* .325 .000 -2.81 -1.09 
3 -1.29* .326 .001 -2.15 -.42 
Based on observed means. 
 The error term is Mean Square (Error) = 5.005. 
*. The mean difference is significant at the 0.05 level. 
 
 The same pattern of estimation accuracy was found for both estimating specific 
test performance with others (F= 20.323, p<.000) and general depression knowledge 
compared to others (F=22.448, p<.000). Overall, top performers were much more 
accurate in their self-assessments, whereas the opposite was true for less knowledgeable 




Fig 7. Difference scores for test score (%) and perceived test score (%) by quartile group 
 
Table 2. Results of the Bonferroni post hoc test for estimated test scores comparisons 
across knowledge test score quartile groups 
Multiple Comparisons 
Dependent Variable: Difference Score MCAT and Estimated Percent Score  
 Bonferroni 




















2 6.51 3.344 .315 -2.36 15.37 
3 9.38* 3.352 .032 .49 18.27 
4 25.17* 3.352 .000 16.28 34.06 
2 
1 -6.51 3.344 .315 -15.37 2.36 
3 2.88 3.344 1.000 -5.99 11.75 
4 18.66* 3.344 .000 9.80 27.53 
3 
1 -9.38* 3.352 .032 -18.27 -.49 
2 -2.88 3.344 1.000 -11.75 5.99 
4 15.79* 3.352 .000 6.90 24.68 
4 
1 -25.17* 3.352 .000 -34.06 -16.28 
2 -18.66* 3.344 .000 -27.53 -9.80 




Fig 8. Difference scores by knowledge test quartiles for % score vs. estimation of general 
knowledge compared to others 
 
Table 3. Results of the Bonferroni post hoc test for general knowledge difference score 
comparisons across knowledge test score quartile groups 
 
 Multiple Comparisons 
Dependent Variable: Difference Score MCAD and Estimated Percent Score  
 Bonferroni 




















2 10.95* 3.491 .011 1.69 20.21 
3 13.11* 3.500 .001 3.82 22.39 
4 28.47* 3.500 .000 19.18 37.75 
2 
1 -10.95* 3.491 .011 -20.21 -1.69 
3 2.16 3.491 1.000 -7.10 11.42 
4 17.52* 3.491 .000 8.26 26.78 
3 
1 -13.11* 3.500 .001 -22.39 -3.82 
2 -2.16 3.491 1.000 -11.42 7.10 
4 15.36* 3.500 .000 6.08 24.65 
4 
1 -28.47* 3.500 .000 -37.75 -19.18 
2 -17.52* 3.491 .000 -26.78 -8.26 










Results of Inferential Statistics for Model 
 In order to test the proposed model’s validity, a series of regression analyses 
following the Baron & Kenny (1986) mediation regression analysis method were 
performed. First, the zero-order relationships of this model were tested. As stated in H1, 
the first relationship of interest is whether level of knowledge about depression predicts 
intention to communicate with one’s physician. 
 H1a: Consumers with a low level of disease knowledge will be more likely to 
 intend to communicate with their physician about a drug than high knowledge 
 consumers. 
 H1b: Consumers with a high level of knowledge about disease will be less likely to 
   intend to request a drug from their physician than low knowledge consumers. 
The analysis revealed that there is no significant relationship between subject’s 
depression knowledge and their intention to communicate with their physician about 
medication (F=2.15, p >.05). Therefore, both H1a and H1b were not supported, as there 
is no relationship between the theorized independent and dependent variables. 
 As H1 is not supported, logically, neither will H2.   









Fig 9. Proposed theoretical model tested in this research 
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 H2: Consumer’s level of domain-specific metacognitive ability will partially 
 explain the negative relationship between level of knowledge about disease 
 and intention to communicate with a physician. 
 There is no linear or predictive relationship between actual and perceived scores. 
Subjects’ performance on the disease knowledge test did not relate to where they 
perceived themselves ranking compared to others in general knowledge (F=0.25, 
p=.618). In addition, their actual disease score performance did not relate to where they 
perceived themselves to rank compared to others on this specific test (F=1.933, p=.165). 
Finally, their raw score on the disease test was not related to what they perceived their 
raw test score to have been (F=.107, p=.744).  
 For thoroughness, a series of regressions were performed in order to assess the 
relationship between metacognitive ability and intention to communicate with the 
physician. It was discovered that subject’s comparisons of their general domain specific 
knowledge to others (F=6.996, p=.009), comparison of their performance on the test 
compared to other test-takers (F=7.949, p=.005) and their estimation of how well they 
performed on the depression knowledge test (F=9.851, p=.002) all significantly related to 
the intention to their communicate with their physician.  
 The final proposed relationship between model variables relating to DTCA was 
assessed.   
 H3a: Low depression knowledge consumers who view a DTC ad will have lower 
 metacognitive awareness than low knowledge consumers who do not view a 
 DTC ad. 
 H3b: High depression knowledge consumers who view a DTC ad will have 
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 metacognitive awareness that does not significantly differ from that of high 
 knowledge consumers who did not view a DTC ad.  
 To test H3a and H3b and determine whether DTCA had any impact on subjects’ 
metacognitive ability, multiple regressions were conducted. Overall, the regressions using 
the three types of metacogntive ability measures were significant (MCAD: F=3.515, 
p=.031; MCAT: F=3.988, p=.019; MCAR: F=4.912, p=.008). However, this was due to 
the metacognitive variables and not the DTCA manipulation. Whether or not subjects 
were exposed to the manipulation in fact had no bearing on whether they intended to 
communicate with their physician regardless of what type of metacognitive measure was 
used: (MCAD: t=.227, p=.821; MCAT: t=.217, p=.828; MCAR: t=.015, p=.988). 
 
Table 4. Summary of hypotheses results 
Hypothesis Conclusion 
Unskilled/Unaware Supported 
H1a Not supported 
H1b Not supported 
H2 Not supported 
H3a Not supported 
H3b Not supported 
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Follow up analysis 
 Although not all initial hypotheses were supported, a direct relationship between 
subjects' perceived level of knowledge and intention to communicate with their physician 
was uncovered.  
 To follow up on this finding, subjects were asked a series of questions that probed 
into their rationale regarding why they would or would not follow up to ask their 
physician for the drug they saw advertised in the DTC ad.  
 Subjects who were exposed to the manipulation were asked if they were 
diagnosed with depression, whether or not they would request the drug they had just seen 
advertised. The majority of individuals reported that they would not do so (Figure 11). 
 
Fig 10. Participants' intention to request the specific drug 
 
 A large portion of low-knowledge respondents stated they trust their doctor to 
know what is best for them and that was why they would not request a drug. In 
comparison, 64% of low knowledge respondents who would request a drug stated they 
would do so because they think they understand their own health condition best. This is 
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shocking, particularly when only half of high knowledge patients who would request a 
drug cited the same reason.  
 
Fig 11. Low knowledge consumers’ rationale for not requesting the advertised drug 
 
 




Fig 13. Low knowledge consumers' rationale for requesting the advertised drug 
 
 





THEORETICAL AND PRACTICAL IMPLICATIONS 
 
 
Measuring intention to communicate with the physician 
 
 In prior research (Bell et al., 1999; Perri & Dickson, 1988; Williams & Hensel, 
1995), the intention to request a drug or talk to a physician was measured using a single 
item. For example, Williams and Hensel (1995) measured drug request intentions by 
asking: “I’m going to ask my doctor about nitroglycerin patches’’ anchored with a Likert-
type scale. Young, Lipowski and Cline (2005) argued that a single point measure simply 
was not enough to capture the consumers’ intention to request a drug. However, this 
suggests that in fact, a single point measure, willingness to talk to one’s physician, may 
be sufficient to predict the likelihood of a patient’s intentions to inquire about a drug to a 
physician. Young, Lipowski and Cline’s (2005) Intention to Communicate with Physician 
measure is composed of seven questions, each on an 11 point scale. Through a factor 
analysis, this research reveals that this level of complexity may not required in order to 
measure this variable. Therefore, although previous research had used a single point 
measure without validation, it may in fact, be the correct and most parsimonious way to 
approach capturing this variable. This finding is significant in that it brings forward a 
more valid and reliable way to measure this variable in future research. 
 
Unskilled and Unaware 
 
 Consistent with previous findings (Kruger & Dunning, 1999; Ehrlinger et al., 
2008), participants in this study conformed to expected results and overestimated how 
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well they performed on the disease knowledge test, both comparatively with others and 
objectively by estimating their own raw score. 
 This advances previous theories in two main ways. Past research in this domain 
has focused mainly on general knowledge tasks. For example, Dunning and Kruger’s 
(1999) seminal research focused on participants’ knowledge in domains of humor, logical 
reasoning and grammar. The fact that individuals still overestimate their abilities even in 
a specialized knowledge domain in which they do not have formal training is significant: 
It suggests that the need to think positively of oneself is deeply engrained. 
 Past research, most notably that of Baumeister (1989), shows that positive 
illusion, whether about oneself or one’s surroundings, is psychologically adaptive. 
Conversely, individuals who have highly accurate perceptions of themselves and their 
environment, often show signs of depression and maladaptive tendencies.  This finding 
supports that general body of work.  
 
Those who are unskilled are also the most unaware 
 
 Results demonstrate that consistent with the ‘Unskilled/Unaware” hypothesis, 
first postulated by Kruger and Dunning (1999), individuals who rank the lowest in 
objective ability are also the ones who most drastically overestimate how well they 
perform. 
 This finding is important theoretically for several reasons. First, prior research of 
this theory had mainly focused on testing student populations (Dunning & Kruger, 1999) 
In the rare instances in which a non-student population has been studied, it was in a 
domain in which the participants had extensive experience (Ehrlinger et al., 2008). This 
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study in novel in that it tests a sample of adults on their knowledge of a domain in which 
the average person is not an expert and has no formal training. Despite these novel testing 
conditions, the unskilled/unaware theory appears to hold.   
 What implications does this result have for pharmaceutical industry stakeholders? 
This finding suggests it is to educate the general public about healthcare issues. As 
Dunning and Kruger (1999) found, increasing objective levels of knowledge in a given 
domain also increases metacognitive ability. Therefore, ironically, the more you know, 
the more you are aware of the limitations and boundaries of your own knowledge. 
Educating consumers about a particular healthcare issue may allow them to place their 
level of knowledge in perspective, understand where their gaps in knowledge lie and 
allow them to have more meaningful conversations with their respective healthcare 
providers.  
 Numerous studies show that patients who visit a physician and ask about, or 
request a prescription are more likely to receive it than those who do not (Kravitz et al., 
2005). Patient involvement in their own healthcare is significant and continues to grow 
(Barlow, Turner & Wright, 2000; Lorig et al., 1999; Shaw & Baker, 2004). These results 
suggest that physicians should be cautious when heeding to their patients requests. Some 
of these requests could be coming from patients who actually have low levels of 
knowledge about the disease and may not even know that their request may be 
unwarranted. Therefore, these results suggest that physicians should invest time in having 
a conversation with their patient who inquires about a drug to ensure that their patient is 
informed and that prescribing a given therapy is truly in the patients’ best interest.    
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Level of knowledge does not predict intention to speak to physician 
 
 The findings of this study suggest that there was no significant relationship 
between the level of knowledge participants achieved in their disease knowledge test and 
their willingness to speak with their physician. Although no conclusive results can be 
drawn from this finding, there are several possibilities of what this result may imply and 
could be tested in future research. First, there are some other variables that may be 
involved in the patients’ decisions to visit their doctor. In An’s (2007) study, perceived 
level of knowledge moderated the relationship between attitude toward DTCA and drug 
inquiry intentions. Therefore, it is possible that attitudes have more impact on speaking to 
one’s physician than cognitive knowledge factors.  
 In terms of what this might mean for policy makers and regulators, there is the 
possibility that pharmaceutical companies’ use of educational advertising may only have 
a negligible effect on consumer’s actually taking the time to visit their physician. What 
may matter more are individuals’ attitudes toward DTCA in general. 
   
Metacognitive ability predicts willingness to speak to ones physician 
 One’s level of perceived knowledge suggests increased willingness to speak to 
one’s physician. Similarly to An’s (2007) finding, this suggests that it is one’s own 
perceptions, attitudes or emotions that play more of a role in visiting the physician than 
the objective level of knowledge. This finding has many implications, particularly for 
health care stakeholders. For regulators, if the objective is to prevent patients from 
seeking out unnecessary treatment, then the goal must also be to change attitudes toward 
DTCA and advertising rather than simply countering promotional tactics with educational 
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ones. For the pharmaceutical industry, this finding suggests that they should be trying to 
heighten positive attitudes and feelings of empowerment in the patient. 
 
DTCA does not have a significant effect on metacognitive ability 
 Results suggest that DTCA had no meaningful effect on metacognitive ability, or 
how one interprets ones own knowledge. Initially, one of the research questions of this 
study was whether DTCA has the effect of making consumers feel more educated 
perhaps without really providing any true educational value. This was postulated due to 
previous research which states that exposure to DTCA increases the potential for 
unwarranted trips to the physician (Murray et al., 2003). However, this was not found to 
be the case. 
 This result suggests that DTCA may be providing actual educational value for 
consumers or really has no effect on perceived knowledge at all. Either way, the potential 
practical implication of this is that regulators concerns about potential misleading 
knowledge found in DTCA may be overstated. Rather, regulators may need to continue 
to focus more specifically on what mechanism links viewing DTCA to drug requests.  
 
Trust in physician decreases with increases in level of self-reported knowledge 
 Descriptive analysis of follow up questions included in the study reveal that there 
is a trend toward those who put less trust in their physician report possessing the highest 
levels of knowledge. Based on the results of this study and previous research (Dunning & 
Kruger, 1999; Dunning, Heath & Suls, 2004; Ehrlinger et al., 2008), patients who self-
report the highest levels of knowledge are not always the most knowledgeable.  
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 Therefore, this finding suggests that there is a risk that individuals with low levels 
of knowledge are not confiding or putting trust in their physician when perhaps they 
should. Take for example, this quote: 
 
“I can get three types of health information: I can print out information from the internet, 
I can read some literature, and I can talk to my doctor. Then I can see whether this 
information is congruent or differs. So, as a layperson, I obtain some kind of medical 
know-how and I can disagree with my doctor” 
 
- Participant response “Using the internet for health information”, Eysenbach & 
Kohler, 2002, p575 
  
 This result provides a possible explanation for why overestimation of one’s 
knowledge is particularly detrimental to that relationship. A bit of knowledge enhances 
patients’ feelings of knowledge and this may incite them to visit their physician. 
 Many have argued that DTCA interferes with the patient physician relationship 
(Mintzes et al., 2003; Kravitz, 2000). Stakeholders on the pro-DTCA side argue that 
education and patient empowerment is truly a step in the right direction and physicians 
just need to adapt from the traditional one-way flow of information from themselves to 
patients (Welch, Cline & Young, 2005; Calfee, 2002). This finding contradicts none of 
these positions. However, it does suggest that patient empowerment must be done 
correctly and thoroughly enough for the patient to not only feel knowledgeable, but be 
knowledgeable so that if they feel the need to go against their physician’s 
recommendations or seek a second opinion, they are doing so to their own benefit.  
 This finding suggests that what regulatory bodies should be most concerned about 
is how to empower physicians to deal with consumers who may come in to their office 





 This validity of this study is limited by several factors that can be improved upon 
in future research. 
 
Measure of depression knowledge 
 
 This study used a measure of gauging participants’ general knowledge about 
depression that was not formally validated. As there was no existing measure that truly 
captured general knowledge about depression for a layperson, two measures intended for 
layperson use were combined to form one measure and was validated by a licensed 
psychologist on the faculty of a teaching hospital. However, there was no validation of 
the measure’s reliability with a pre-existing depression knowledge scale because one 
does not exist.  
 
 Sample Selection 
 Sample selection for this study was not random. Although CanView takes a 
sample that reflects general demographics of Canada, participants are part of a panel. 
Therefore, the behavioral, psychological and other characteristics of this panel may not 
necessarily match those in the general population from a random sample. However, 
participants were randomized across control and test conditions to eliminate any biases 
within the sample itself.  
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Administration of the manipulation (DTC ad) 
 Another limitation of this study is the way in which the manipulation was 
administered to participants. Exposure to DTCA may not be ecologically valid and does 
not reflect how individuals are exposed to DTCA in a non-experimental setting. For 
example, this study is cross-sectional and cannot capture the effect of long-term exposure 
to DTCA over time and across media. The lack of ecological validity in this study 
reduces confidence in external validity and ability to generalize findings.  
 
Mediating and moderating variables 
  
 While efforts were made to capture relevant variables in this study, not all 
hypothesized results were found to be significant. Therefore, the model originally 
proposed is lacking explanatory power in the form of other variables that would better 
explain the path from consumer’s knowledge to intention to communicate with the 
physician.  
 The focus of this study was on cognitive factors that affect intention to talk to the 
physician. This study did not address other environmental factors, personality factors or 
social factors. However, other research is beginning to study these factors. For example, 
certain authors are beginning to investigate the impact of socio-cultural factors, such as 
the society-wide increased focus on health issues (Brennan et al., 2010; Davis, 2006; 
Poitras & Meredith, 2009) and how that relates to medicalization. However, the scope of 




DIRECTIONS FOR FUTURE RESEARCH 
 
 
What environmental factors are causing increases in perceived level of knowledge?  
 
 One of the most pressing questions that arise from this study is what factors are 
causing individuals to overestimate their disease knowledge. There is a plethora of 
research which states that individuals are innately biased to over estimate their abilities 
(Dunning & Kruger, 1999; Ehrlinger et al., 2008; Dunning et al., 2004; Ehrlinger & 
Dunning, 2003; Dunning et al. 1989), think positively about themselves (Baumeister, 
1989) and even rationalize that other are more prone to making these types of biased 
judgment than themselves (West, Meserve & Stanovich, 2012).  
 The next wave of research in this domain would be well served by investigating 
potential moderators of this effect in the health domain. Being able to determine what 
factors heighten positive self-perceptions and what factors actually push individuals to go 
from overestimating their disease knowledge to making a trip to their doctor’s office 
would be informative and have profound implications for both regulators and the 
pharmaceutical industry alike.  
 
Does disease category matter? 
 In this study, depression was used as the disease in question as it is common to 
both men and women and is frequently the subject of DTCA. However, Keselman et al. 
(2008) found in their work that participants had a particular difficult time retrieving a 
correct diagnosis of angina based on symptoms provided, possibly because no one knew 
what angina was. Therefore, it is open to question of whether a more obscure, less 
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frequently advertised disease were used in this type of research whether similar results 
would be obtained.  
 It would be interesting to see just how far consumer’s self deception goes. For 
example, if participants were presented with an ad for Johnson & Johnson’s Cypher™ 
and asked about their knowledge of percutaneous transluminal coronary angioplasty, it 
would be interesting to see whether results would be similar and whether the same biases 
of overestimation of knowledge would still appear. Investigating this would have much 
practical value should DTCA in the U.S. broaden to less familiar categories as it did in 
2007 by Johnson & Johnson (Boden & Diamond, 2008).  
 
Do other forms of DTCA affect metacognitive ability? 
 
 Results from this study show that branded DTCA may not have any effect on 
metacognitive ability, which in turn influences likelihood to go visit a physician. 
However, it would be important to determine whether other forms of DTCA have the 
same effect. It would be interesting to see whether educational ads or reminder ads have a 
similar null effect on metacogntiive ability. Future research should investigate this in 
order to have a fuller picture of the influences of all forms of DTCA. This would have 
important consequences for regulators in both the U.S. and Canada.  
 
The impact of an educational intervention 
 In their research, Dunning and Kruger (1999) found that the best way to reduce 
individuals’ biases of overestimating their knowledge was to actually improve their level 
of knowledge. In this case, it is important to determine whether this would also be the 
79 
case in the healthcare domain. In addition, there would be practical implications as well 
for determining whether educating consumers could potentially decrease the number of 
unnecessary visits to health care professionals.  
 
How to empower physicians and health care professionals 
 One of the realities that all stakeholders must come to terms with is that with the 
vast amount of information now available to consumers (particularly via the internet), is 
here to stay. Consumers now have access to information, both correct and incorrect, and 
that is a reality that physicians and regulators must deal with. What this study suggests is 
that there is a risk of consumers visiting their physician feeling knowledgeable without 
this in fact being the reality. Physicians often emphasize that DTCA is a burden to them 
because it takes time away from practicing medicine when they have to explain to 
patients that, for example, the latest drug they have seen or heard about is actually not 
suitable for them (Shaw & Baker, 2004). Future research should focus on the best 
practices of how to train physicians to deal with these types of situations in a positive and 





 This study and future research investigating the causes of prescription drug 
request will be able to add insight into how consumers operate in the healthcare 
marketing domain. Ultimately, future research should be synthesized in order to develop 
a model of how patient-directed pharmaceutical advertising affects the consumer and 
how that interacts with other social, environmental, demographic and psychological 
variables. One day, having this level of understanding and power to predict at what point 
a consumer will reach out to a health care professional about a drug will be a very 
powerful tool. This knowledge and understanding will have implications for all 
stakeholders involved: regulatory, the pharmaceutical industry, government and most 
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APPENDIX A: NORMAL DISTRIBUTION ASSUMPTION 
 
Depression knowledge raw test score 
 
 
Metacognitive ability estimated general knowledge score 
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APPENDIX B: FACTOR ANALYSIS OF INTENTION TO 

















APPENDIX C: GENERAL OVERESTIMATION OF PERFORMANCE 
 









Paired samples t-test comparing perceived general depression knowledge and actual 




APPENDIX D: COMPARING DIFFERENCE SCORES ACROSS ACTUAL 
DEPRESSION KNOLWEDGE SCORE QUARTILE GROUPS 
 

















APPENDIX E: REGRESSION ANALYSIS TESTING H1 
 
Variables Entered/Removeda 
Model Variables Entered Variables Removed Method 
1 Raw Test Scoreb . Enter 
a. Dependent Variable: Intention to Communication with Physician (ICB) 






Model Sum of Squares df Mean Square F Sig. 
1 
Regression 1.383 1 1.383 2.150 .143b 
Residual 241.343 375 .644   
Total 242.727 376    
a. Dependent Variable: Intention to Communication with Physician (ICB) 





Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .075a .006 .003 .802 
a. Predictors: (Constant), Raw Test Score 
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APPENDIX F: REGRESSION OF LEVEL OF DEPRESSION 
KNOWLEDGE ON METACOGNITIVE ABILITY MEASURES 
TESTING H2. 
 
Metacognitive ability: Estimated general depression knowledge 
Variables Entered/Removeda 
Model Variables Entered Variables 
Removed 
Method 
1 Raw Test Scoreb . Enter 
a. Dependent Variable: Estimated General Depression Knowledge 
(%) 






Model Sum of Squares df Mean Square F Sig. 
1 
Regression 134.116 1 134.116 .250 .618b 
Residual 201522.117 375 537.392   
Total 201656.233 376    
a. Dependent Variable: Estimated General Depression Knowledge (%) 





Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .026a .001 -.002 23.182 
a. Predictors: (Constant), Raw Test Score 
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Metacognitive ability: Estimated test-specific depression knowledge 
Variables Entered/Removeda 
Model Variables Entered Variables Removed Method 
1 Raw Test Scoreb . Enter 
a. Dependent Variable: Estimated Test Performance (%) 






Model Sum of Squares df Mean Square F Sig. 
1 
Regression 955.962 1 955.962 1.933 .165b 
Residual 185468.972 375 494.584   
Total 186424.934 376    
a. Dependent Variable: Estimated Test Performance (%) 
b. Predictors: (Constant), Raw Test Score 
 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .072a .005 .002 22.239 
a. Predictors: (Constant), Raw Test Score 
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Metacognitive ability: Estimated raw score depression knowledge 
Variables Entered/Removeda 
Model Variables Entered Variables Removed Method 
1 Raw Test Scoreb . Enter 
a. Dependent Variable: Estimates Raw Test Score (Out of 11) 






Model Sum of Squares df Mean Square F Sig. 
1 
Regression .468 1 .468 .107 .744b 
Residual 1645.903 375 4.389   
Total 1646.371 376    
a. Dependent Variable: Estimates Raw Test Score (Out of 11) 






Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .017a .000 -.002 2.095 
a. Predictors: (Constant), Raw Test Score 
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APPENDIX G: TESTING H2. REGRESSION OF METACOGNITIVE 
ABILITY MEASURES TO INTENTION TO COMMUNICATE WITH 
PHYSICIAN 
 




Metacognitive ability: Estimated test-specific depression knowledge 
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APPENDIX H: MULTIPLE REGRESSION OF MODEL INCLUDING 
DTCA INTERVENTION TESTING H3. 
 
Metacognitive ability: Estimated general depression knowledge 
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Metacognitive ability: Estimated raw score depression knowledge 
 
